Ebola Outbreak: Uganda Set To Start Vaccine Trials

Updated Feb 3, 2025 | 08:58 AM IST

SummaryAfter a nurse died of the Ebola virus, the country has declared Ebola outbreak and is now deploying vaccine against the Sudan strain of the virus.
Ebola vaccines

On Thursday, Uganda confirmed an outbreak of the Ebola virus in its capital city Kampala, with the first confirmed patient dying from it a day before. As per the new developments, the officials are now preparing to deploy a trial vaccine to put an end to this outbreak.

Groups of scientists are working on the vaccine and deployment of more than 2,000 doses of a candidate vaccine against the Sudan strain of Ebola has been planned and confirmed by the Uganda Virus Research Institute. As per the World Health Organization (WHO), Uganda has access to 2,169 doses of trial vaccine. For now, however, there are no approved vaccines for the strain and officials are still investigating the source of the outbreak.

The WHO had also allocated $1 million from its contingency fund for emergencies to support quick action and contain the outbreak in the country.

Confirmed Case

On Wednesday, the Sudan strain of Ebola killed a nurse employed at Kampala's main referral hospital. It is after his death that Ebola was declared an outbreak in the country. Post-mortem samples too have confirmed the Sudan Ebola Virus Disease and at least 44 contacts of the deceased man have been listed for tracing. 30 of these are health workers.

Ebola is a highly infectious hemorrhagic fever, which is transmitted through contact with bodily fluids and tissue. Symptoms include headache, vomiting of blood, muscle pains and bleeding.

it was in the late 2022, when Uganda had last suffered an Ebola outbreak. It killed 55 of the 143 people who were infected and was declared over on January 11, 2023.

What Is Ebola Virus Disease?

As per the WHO, Ebola virus disease (EVD) is a rare but severe illness in humans and is often fatal. People can get infected with the virus if they touch an infected animal when preparing food, or touch body fluids of an infected person such as saliva, urine, faeces or semen, or things that have body fluids of an infected person like clothes or sheets.

How Does Transmission Work?

Ebola enters the body through cuts in the skin or when one is touching their eyes, nose or mouth. Early symptoms include fever, fatigue and headache.

It was first discovered in 1976 in two simultaneous outbreak, when in Nzara, South Sudan and other in Yambuku, Democratic Republic of Congo. The latter occurred near a village near the Ebola River, which is where it gets its name from.

It is highly infectious and transmissible disease, in fact, there have been cases of health-care workers who have frequently been infected while treating patients with suspected or confirmed Ebola. This occurs through close contact with patients when infection control precautions are not practiced strictly.

Cases of people conducted burial ceremonies, involving direct contact with the body of the deceased too can lead to the transmission of Ebola. Even after the long suffering and recovery, there is a possibility of sexual transmission. Pregnant women who get acute Ebola and recover may still carry the virus in their breastmilk, or in pregnancy related fluids and tissues.

Symptoms:

  • feeling tired
  • headache
  • muscle and joint pain
  • eye pain and vision problems
  • weight gain
  • belly pain and loss of appetite
  • hair loss and skin problems
  • trouble sleeping
  • memory loss
  • hearing loss
  • depression and anxiety

End of Article

Liverpool Legend John Toshack Diagnosed With 'Terrible Disease' Dementia

Updated Mar 26, 2026 | 02:00 AM IST

SummaryJohn Toshack's memory of his glory days remains intact, but his short-term memory is more affected. His son Cameron said that his father has "good days and bad days".
Liverpool Legend John Toshack Diagnosed With 'Terrible Disease' Dementia

Credit: FAWales/X

John Toshack, the Wales and Liverpool legend, has been diagnosed with dementia, his son Cameron has confirmed to the media.

After a glittering playing career with Liverpool, the now 77-year-old Toshack went on to manage several leading clubs across Europe, including Real Madrid, Real Sociedad, and Besiktas.

His son and ex-Leeds United assistant Cameron, now coaching in Thailand, told the Daily Mail that his father has "good days and bad days".

"It's a terrible disease," he added.

Cameron noted that while his father's memory of his glory days remains intact, his short-term memory is more affected. And his father often tends to forget matters they spoke about in short periods.

"It’s the short-term memory where we’re seeing it – I speak to him most days, and if we chat in the afternoon, he might not remember that we also spoke in the morning," the report said.

"But if I ask him about the Liverpool days, or Sociedad or Madrid, the detail is amazing; his memory was so clear".

Meanwhile, Football Association of Wales in a post on social media platform X shared: "Our thoughts are with former

@Cymru player and manager John Toshack and his family following his recent diagnosis".

What Is Dementia?

Dementia is an umbrella term used to describe a significant decline in mental function that is serious enough to affect everyday life. It commonly impacts memory, thinking, and reasoning skills.

Dementia itself is not a single disease but a collection of symptoms caused by underlying conditions such as Alzheimer’s disease or vascular dementia.

Common signs include memory problems, confusion, difficulty finding words, changes in mood or behaviour, and trouble completing familiar tasks.

These symptoms usually worsen over time and are not considered a normal part of ageing. Although there is no cure, treatment options can help manage symptoms, and early diagnosis plays an important role in care planning.

Alzheimer’s Disease: The Leading Cause of Dementia

Alzheimer's disease is one of the most common forms of dementia and mostly affects adults over the age of 65.

About 8.8 million Indians aged 60 and above are estimated to be living with Alzheimer's disease. Over seven million people in the US, 65 and older, live with the condition, and over 100,00 die from it annually.

Alzheimer's disease is believed to be caused by the development of toxic amyloid and beta proteins in the brain, which can accumulate in the brain and damage cells responsible for memory.

Amyloid protein molecules stick together in brain cells, forming clumps called plaques. At the same time, tau proteins twist together in fiber-like strands called tangles. The plaques and tangles block the brain's neurons from sending electrical and chemical signals back and forth.

Over time, this disruption causes permanent damage in the brain that leads to Alzheimer's disease and dementia, causing patients to lose their ability to speak, care for themselves, or even respond to the world around them.

While there is no clear cause of Alzheimer's disease, experts believe it can develop due to genetic mutations and lifestyle choices, such as physical inactivity, unhealthy diet, and social isolation.

Early symptoms of Alzheimer's disease include forgetting recent events or conversations. Over time, Alzheimer's disease leads to serious memory loss and affects a person's ability to do everyday tasks.

There is no cure for this progressive brain disorder, and in advanced stages, loss of brain function can cause dehydration, poor nutrition, or infection. These complications can result in death.

End of Article

Drug Resistance Driving Severe Typhoid Disease, Death Among Children Under-5s in India: Lancet Study

Updated Mar 25, 2026 | 07:00 PM IST

SummaryTyphoid fever caused an estimated 4.9 million cases and nearly 8,000 deaths in India in 2023. And children under-5 accounted for a large proportion of infections with resistance to fluoroquinolones, one of the main classes of antibiotics used to treat typhoid.
Drug Resistance Driving Severe Typhoid Disease, Death Among Children Under-5s in India: Lancet Study

Credit: Canva

Children under 5 in India remain at high risk of typhoid infections, hospitalization, and death due to growing antimicrobial resistance (AMR), according to an alarming study, which highlighted the urgent need to control drug resistance in the country.

Typhoid fever is a systemic illness caused by Salmonella enterica serovar Typhi (S. Typhi), and presents a significant health challenge in India.

The modelling study, published in The Lancet Regional Health – Southeast Asia, showed that typhoid fever caused an estimated 4.9 million cases and nearly 8,000 deaths in India in 2023.

However, more concerning was that a large proportion of infections were found resistant to fluoroquinolones — one of the main classes of antibiotics used to treat typhoid. They found that:

  • Children aged 5–9 years had the highest number of typhoid fever cases and AMR cases
  • Children aged 6 months to 4 years experienced the highest number of hospitalizations and deaths.

"Drug-resistant typhoid fever remains a serious public-health threat in India, with implications beyond national borders," said Dr Vijayalaxmi Mogasale, Joint PhD Candidate at the London School of Hygiene & Tropical Medicine and Nagasaki University.

"Tackling this problem does not lie solely in moving to newer antibiotics, but calls for timely preventive action, including responsible antibiotic use and the introduction of the typhoid vaccine into the national immunization program, prioritizing high-burden age groups and regions," she added.

Also read: Study Links Widespread Use of Antibiotics During COVID To Surge In AMR Cases

Typhoid: AMR A Major Concern In India

In Global Burden of Diseases (GBD) 2021, India contributed to 58 percent of global typhoid fever cases and 48 percent of global deaths.

The new study, including researchers from Christian Medical College in Vellore, estimated that more than two-thirds of typhoid cases in India are resistant to fluoroquinolones. This not only limits treatment options but also increases the risk of complications.

The major drivers of typhoid fever deaths were identified among those with no treatment and hospitalized cases with AMR-related complications. The highest burden of typhoid cases were reported from Delhi, Maharashtra, and Karnataka.

Further, the study found that drug-resistant typhoid infections accounted for at least 87 per cent of India's disease-related economic burden in 2023, the PTI reported.

The total economic burden due to typhoid fever was estimated at Rs 123 billion.

Children under the age of 10 incurred the highest economic burden, contributing to over half of the costs, researchers found.

In addition, they estimated that households bore 91 per cent of expenses, and 70,000 families faced "catastrophic" health expenditure.

A 2024 ICMR report also flagged that more Indians are developing antibiotic resistance against typhoid, pneumonia, and urinary infections. Over 95 percent of Salmonella typhi strains are now resistant to fluoroquinolones, making it difficult to treat infections caused by this bacterium.

Also read: Antimicrobial Resistance Explained: Why Is WHO Calling It A Serious Health Threat?

Typhoid: How Vaccines Can Help

Typhoid fever is a water- and food-borne infectious disease. Major symptoms include

  • high fever,
  • fatigue,
  • headache,
  • abdominal pain.
The effective typhoid conjugate vaccine (TCV) is available in India through private healthcare. In 2022, it was recommended to be added into the Universal Immunization Program.

The World Health Organization (WHO) recommends TCV for children from six months of age and for adults up to 45–65 years, depending on the vaccine.

To achieve greater impact, the Lancet researchers suggested implementing:

  • A broader catch-up or school-based vaccination campaigns
  • controlling the broader strategy of antimicrobial stewardship
  • Making improvements in water, sanitation, and hygiene.

End of Article

US CDC Warns Of New Immune-Evasive COVID Variant In 23 Countries

Updated Mar 25, 2026 | 02:00 PM IST

SummaryBA.3.2 is a descendant of the Omicron BA.3 lineage., and has been designated as a Variant Under Monitoring (VUM) by the World Health Organization. The strain does not boost immunity from previous infection or vaccination. However, the global health body noted that currently approved COVID-19 vaccines are expected to continue protecting against severe disease.
US CDC Warns Of New Immune-Evasive COVID Variant in 23 Countries

Credit: iStock

The US Centers for Disease Control and Prevention (CDC) has raised concerns about a highly mutated variant of COVID-19 -- BA.3.2 -- which has been reported in at least 23 countries, including 25 states in America.

The BA.3.2 variant was first identified in a respiratory sample in South Africa in November 2024.

The World Health Organization (WHO) has designated BA.3.2 as a Variant Under Monitoring (VUM). It does not boost immunity from previous infection or vaccination.

What makes the BA.3.2 variant special is the “70 to 75 substitutions and deletions in the gene sequence of its spike protein”, according to the CDC’s latest Morbidity and Mortality Weekly Report.

“BA.3.2 represents a new lineage of SARS-CoV-2, genetically distinct from the JN.1 lineages (including LP.8.1 and XFG) that have circulated in the US since January 2024,” said the CDC researchers.

“BA.3.2 mutations in the spike protein have the potential to reduce protection from a previous infection or vaccination,” they added.

What Is The BA.3.2 Variant?

BA.3.2 is a descendant of the Omicron BA.3 lineage. It is genetically distinct from the previously circulating JN.1 lineages (including LP.8.1 and XFG).

BA.3.2 comprises two major branches, BA.3.2.1 and BA.3.2.2. BA.3.2.2 also has substitutions like: K356T, A575S, R681H, and R1162P, the CDC report said.

The first BA.3.2 lineage sequence was detected in a respiratory sample collected on November 22, 2024, in South Africa from a boy aged 5 years.

It was then identified in 2025, in Mozambique (March), the Netherlands (April), and Germany (April). It began to increase in September 2025, with the highest number of detections reported during the week beginning December 7, 2025.

As of February 11, 2026, BA.3.2 had been detected in at least 23 countries.

Between November 2025 and January 2026, the weekly BA.3.2 detections increased and reached approximately 30 percent of sequences reported in three European countries (Denmark, Germany, and the Netherlands).

BA.3.2 In The US

The strain was detected in the US on June 27, 2025, through the CDC’s Traveler-Based Genomic Surveillance program in a participant traveling to the US from the Netherlands.

The first US detection of BA.3.2 in a clinical specimen collected from a patient was reported on January 5, 2026. Since then, the CDC has detected the BA.3.2 variant from

  • nasal swabs collected from 4 US travelers,
  • clinical samples from 5 patients,
  • 3 airplane wastewater samples,
  • 132 wastewater surveillance samples from 25 states in the US.
  • Till February 11, the strain has been prevalent among 2,579 total genetic sequences.

The CDC stressed the need for “continued genomic surveillance to track SARS-CoV-2 evolution and determine its potential effect on public health”.

BA.3.2 A Variant Under Monitoring

According to the WHO, BA.3.2 demonstrates antigenic drift and reduced neutralization in vitro from previously infected or vaccinated individuals.

However, the global health body noted that currently approved COVID-19 vaccines are expected to continue providing protection against severe disease.

Despite immune evasion, phenotypic data suggest BA.3.2 has reduced infectivity.

It shows resistance to some monoclonal antibodies (cilgavimab, bebtelovimab, sotrovimab) but increased sensitivity to tixagevimab-be, the WHO said.

End of Article